Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{170515,
        author = {Mr. Vaibhav Manikrao Hiwale and Mr. Kuldeep Sukhdeo Kanadje and Dr. D. K. Vir and Mr. Abhishek Raosaheb Ghule and Mr. Hemant Machhindra Kakde and Mahesh Gajanan Farkade and Vaibhav Ramesh Gorade},
        title = {Systemic Review on Cardiotoxicity in the Era of Immuno-Oncology},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {7},
        pages = {454-463},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=170515},
        abstract = {The advent of immuno-oncology (IO) has revolutionized cancer treatment, particularly with the introduction of immune checkpoint inhibitors (ICIs) like anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapies. These agents have demonstrated remarkable efficacy in various cancers by enhancing the immune system's ability to detect and destroy tumor cells. However, along with their clinical benefits, ICIs have introduced a range of immune-related adverse events (irAEs), among which cardiotoxicity, though rare, has emerged as a significant concern. Cardiotoxicity in the context of IO therapies includes myocarditis, pericarditis, heart failure, and arrhythmias. Myocarditis, in particular, can present with high morbidity and mortality, necessitating early recognition and intervention. The underlying mechanism is believed to involve immune-mediated inflammation of cardiac tissues, likely due to the overlap between tumor-associated antigens and self-antigens, leading to off-target effects on the myocardium. The incidence of cardiotoxicity with IO therapies is relatively low compared to other irAEs but can be life-threatening when it occurs. Studies suggest that patients with preexisting cardiovascular conditions may be at higher risk, and thus, the role of cardio-oncology has become pivotal in managing such patients. Emerging strategies to mitigate these risks include vigilant cardiovascular monitoring, the use of corticosteroids to manage inflammation, and collaborations between oncologists and cardiologists to ensure comprehensive care. As immuno-oncology continues to evolve, understanding and managing the risks of cardiotoxicity is crucial for optimizing patient outcomes. This review highlights the mechanisms, clinical manifestations, and management strategies of cardiotoxicity associated with immuno-oncology treatments, underscoring the need for further research to develop predictive biomarkers and safer therapeutic approaches.},
        keywords = {Arrhythmia; Cancer immunotherapy; Cardiotoxicity; Cardiovascular toxicity; Immune system; Myocarditis.},
        month = {December},
        }